Company
Imugene Ltd
ASX:IMU
Imugene Ltd is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours. The company's unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Imugene is supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.
224 stories · page 6 of 12
Imugene seeks to activate immune system of cancer patients to identify and eradicate tumours
The company is well-funded to deliver on commercial and clinical milestones including the development of CF33, PD1-Vaxx and HER-Vaxx treatments.
Imugene director shows faith in company by exercising options and increasing holding to 13.7 million shares
Imugene is a clinical-stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.
Imugene presents HER-Vaxx cancer immunotherapy program at ESMO World Congress on Gastrointestinal Cancer 2021 annual meeting
Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.
Imugene collaborator wins FDA Investigational New Drug approval to initiate CHECKvacc phase one trial
Imugene managing director and chief executive officer Leslie Chong called the approval a “major milestone” for the company as it prepares to commence a phase one trial into metastatic, triple-negative breast cancer with its CHECKvacc drug c
Imugene makes key business development appointment
The company believes new chief business officer Dr Monil Shah will make a valuable contribution to advance its immuno-oncology programs.
Imugene believes it has found “the holy grail of cancer therapy”
By combining its cancer-killing virus with CAR T therapy, Imugene hopes to destroy solid tumours.
Imugene MD and chairman demonstrate faith in company by exercising options with total value of $2.524 million
The company has enhanced its portfolio with a novel CD19 expressing oncolytic virus from City of Hope to be developed in combination with CD19 CAR T cell therapy.
Imugene licenses CD19 Oncolytic virus from City of Hope to turn CAR T therapy against solid tumours
The company has enhanced its portfolio with novel CD19 expressing oncolytic virus from City of Hope to be developed in combination with CD19 CAR T cell therapy.
Imugene has HER-Vaxx Phase 1B Data published in prestigious clinical cancer research journal
HER-Vaxx is a B-cell peptide cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.